잉글우드랩 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 코스메카코리아, was filed 25 Mar 2026.
잉글우드랩: what insiders have been doing
잉글우드랩 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). 1 insider has disclosed 5 filings since 2 November 2025.
The flow runs one way only: 1 insider bought (2 purchases) and nobody sold on the market. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 5 filings here. Our records for 잉글우드랩 go back to 2025, with 2 purchases and no sales on the open market in total.
The latest purchase dates back some time: it was published 230 days ago, on 25 March 2026.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -47.4%Entry ₩12,810 · Close 30 Oct 2026 ₩6,740
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About 잉글우드랩
Ingled Lab is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
